China SXT Pharmaceuticals, Inc. SXTC
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -43.89% | -43.89% | -24.45% | -24.45% | -7.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.89% | -43.89% | -24.45% | -24.45% | -7.85% |
| Cost of Revenue | -46.29% | -46.29% | -24.47% | -24.47% | -6.14% |
| Gross Profit | -36.80% | -36.80% | -24.48% | -24.48% | -12.42% |
| SG&A Expenses | -59.07% | -59.07% | 733.20% | 733.20% | 132.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -56.14% | -56.14% | 374.55% | 374.55% | 147.12% |
| Operating Income | 61.61% | 61.61% | -893.26% | -893.26% | -128.14% |
| Income Before Tax | 106.55% | 106.55% | -693.52% | -693.52% | -137.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 106.55% | 106.55% | -693.52% | -693.52% | -137.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 106.55% | 106.55% | -693.52% | -693.52% | -137.91% |
| EBIT | 61.61% | 61.61% | -893.26% | -893.26% | -128.14% |
| EBITDA | 63.40% | 63.40% | -1,006.84% | -1,006.84% | -127.57% |
| EPS Basic | -- | 0.00% | 11.49% | 11.49% | -106.11% |
| Normalized Basic EPS | -- | -- | -- | -- | -105.74% |
| EPS Diluted | -- | 0.00% | 11.49% | 11.49% | -106.11% |
| Normalized Diluted EPS | -- | -- | -- | -- | -105.74% |
| Average Basic Shares Outstanding | -- | -- | -- | -- | 520.47% |
| Average Diluted Shares Outstanding | -- | 0.00% | 252.32% | 252.32% | 520.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |